European Companies Search Engine
EU funding (€9,975,979): Effective and Affordable Flu Vaccines for the World Hor12 Feb 2020 EU Research and Innovation programme "Horizon"
Overview
Text
Effective and Affordable Flu Vaccines for the World
Despite the availability of flu vaccines for decades, influenza is still an important disease in both developing and developed countries with 500,000 casualties annually and many more people affected. From a global health perspective, the lack of effectivity, availability, affordability and accessibility of flu vaccines significantly limits our ability to respond to the seasonal flu every year and in the event of a pandemic. Currently, a low vaccine effectivity of 40% implies that 60% of vaccinated people are not sufficiently protected, with low confidence further contributing to limited uptake/immunization. In this project, public and private R&D organizations in India, EU and US collaborate on the development of two novel influenza vaccine concepts that meet the requirements of global vaccination, aiming to achieve <10% instead of 60% non-responders, lower costs, and better accessibility. The first approach combines a low dose of a commercial, inactivated, seasonal flu vaccine with a novel, potent adjuvant, and will deliver proof-of-concept in Phase I and IIa trials within 5 years. The second approach builds on three innovations: 1) a novel recombinant HA with increased immunogenicity, 2) a potent adjuvant, and 3) an easy, needle-free delivery by intradermal patches. Contra-productive parts of HA will be removed to increase the immunogenicity of neutralizing epitopes. The adjuvant further stimulates protective immunity and immunological memory. The use of intradermal patches opens possibilities for self-administration, which will improve vaccine uptake in developing as well as developed countries. With proven nonclinical immunogenicity and safety, we will embark on clinical development of this concept after completion of the project. These plans differ in complexity and timelines but are realistic with chances to deliver next-generation flu vaccines for the globe.
Funded Companies:
| Company name | Funding amount |
| CBCI Society for Medical Education | €0.00 |
| Cellvax | €990,443 |
| €0.00 | |
| €0.00 | |
| Council OF Scientific AND Industrial Research | €0.00 |
| €806,043 | |
| Expres2ION Biotechnologies ApS | €610,338 |
| Gennova Biopharmaceuticals Ltd. | €0.00 |
| Institut National de la Sante et de la Recherche Medicale | €943,281 |
| €2,376,154 | |
| Stanipharm | €740,250 |
| Stichting Amsterdam UMC | €1,117,198 |
| €0.00 | |
| Universiteit Gent | €1,104,784 |
| Universiteit Van Amsterdam | €342,500 |
| Viroclinics Biosciences B.V. | €167,270 |
| Vismederi Srl | €777,720 |
Source: https://cordis.europa.eu/project/id/874653
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "CBCI Society for Medical Education - EU funding (€9,975,979): Effective and Affordable Flu Vaccines for the World"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
